[July 25, 2017]

Oncology Drug Discovery Services Market, 2017-2030 - Research and Markets

The "Oncology Drug Discovery Services Market, 2017-2030" report has been added to Research and Markets' offering.

The Oncology Drug Discovery Services Market, 2017-2030 report features an extensive study of the current market landscape and the future potential of CROs providing drug discovery services in oncology.

Cancer, one of the leading causes of death worldwide, is an extremely complex disease and medical science is still struggling to figure out the various factors associated with the disease's origin, propagation, spread (metastasis) and relapse. In fact, in 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer.

With the increasing complexity of drug discovery and development process, the overall spending on R&D in the pharmaceutical / biotechnology sector has increased over the past few years. According to one particular source, this speding has increased from USD 108 billion in 2006 to USD 145 billion in 2016. Heavy investments are being made towards the discovery of novel approaches for the treatment of various types of cancers.

The industry is currently under tremendous pressure not only to meet the expectations of a growing patient population but also to identify ways to address the risks associated with novel drug discovery programs. Over the years, CROs offering drug discovery services have contributed significantly and have now grown to become an integral and indispensable part of the pharmaceutical and biotechnology industry.

This study presents an in-depth analysis of a diverse set of companies that offer services across the different steps, such as target identification, target validation, hit generation, hit-to-lead and lead optimization, of the drug discovery process.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. CROs: End-to-End Service Providers

6. CROs: Target (News - Alert) Based Service Providers

7. CROs: Hit / Lead Based Service Providers

8. CROs: Lead Optimization Service Providers

9. Market Sizing and Forecast

10. Benchmark Analysis

11. Recent Collaborations

12. Future Growth Opportunities

13. Survey Analysis

14. Conclusion

15. Interview Transcripts

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

For more information about this report visit https://www.researchandmarkets.com/research/wdpvgl/oncology_drug

View source version on businesswire.com: http://www.businesswire.com/news/home/20170725006036/en/

[ Back To TMCnet.com's Homepage ]